Postprandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with intensive subcutaneous regimens, in insulin-dependent diabetes mellitus patients

The American Journal of Medicine
D M NathanD Simon

Abstract

To examine the mechanism of the decreased frequency of severe hypoglycemia with implantable pump therapy compared with subcutaneous intensive therapy. Eight subjects with insulin-dependent diabetes mellitus (IDDM), enrolled in an implantable insulin pump study, were admitted to the General Clinical Research Center and on 2 separate days were given either a dose of preprandial insulin chosen to maintain normoglycemia for a standard (450 kcal, 50% carbohydrate) breakfast or 1.75 times the dose. The two doses were administered subcutaneously (by syringe or with an external pump) during one inpatient admission and by implantable pump (intraperitoneally, n=6; or intravenously, n=2) during a separate admission. Blood glucose, plasma-free insulin, and neurocognitive function were measured for 4 hours after the meal. Subcutaneous administration resulted in 7 episodes of hypoglycemia (2 with the usual dose and 5 with the 1.75-fold dose), defined as blood glucose less than 50 mg/dL; implantable pump treatment resulted in only 2 episodes, both with the 1.75-fold dose (P <0.05, Fisher's two-tailed test for implantable versus subcutaneous). Compared with subcutaneous delivery, implantable pump therapy provided significantly lower insulin le...Continue Reading

References

Jul 1, 1978·The Journal of Clinical Endocrinology and Metabolism·M N Shahshahani, Kitabchi
Sep 1, 1990·Diabetes Care·J BrangeA Vølund
Oct 1, 1988·Diabetes Care·M SpraulM Berger

❮ Previous
Next ❯

Citations

Apr 9, 2014·BMC Endocrine Disorders·Peter R van DijkHenk Jg Bilo
Sep 11, 2001·Journal of the American College of Surgeons·K HanazakiF C Brunicardi
Dec 3, 2008·Langenbeck's Archives of Surgery·Jan Willem HavemanAdri M Blomme
Oct 4, 2003·Diabetes & Metabolism·P Schaepelynck BélicarV Lassmann-Vague
Jun 23, 2015·Fundamental & Clinical Pharmacology·Stéphanie DalSéverine Sigrist
Oct 26, 2011·Diabetes·Claudio CobelliBoris Kovatchev
Nov 19, 2005·Expert Review of Medical Devices·Bogdan Catargi
Jun 7, 2006·Minimally Invasive Therapy & Allied Technologies : MITAT : Official Journal of the Society for Minimally Invasive Therapy· Renard
Jul 5, 2017·Diabetes, Obesity & Metabolism·Véronique GingrasRémi Rabasa-Lhoret
Jan 22, 2010·The Cochrane Database of Systematic Reviews·Marie L MissoJonathan Shaw
Mar 1, 2019·Xenotransplantation·Naho IizukaShinichi Matsumoto
Jun 28, 2017·Journal of Diabetes Science and Technology·Rosa Garcia-VerdugoOliver Schnell
Jul 15, 2004·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·C E AhlforsA T Cheung
Jul 6, 2019·Endocrine Reviews·Rayhan A LalBruce Buckingham
Mar 14, 2020·Therapeutic Advances in Endocrinology and Metabolism·Peter R van DijkHenk J G Bilo
Jun 28, 2011·Diabetes Technology & Therapeutics·Alfred PenfornisSophie Borot
Oct 9, 2019·Endocrinology, Diabetes & Metabolism·Peter R van DijkHenk J G Bilo
Jun 13, 2021·Journal of Controlled Release : Official Journal of the Controlled Release Society·Jia HeDiane J Burgess

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.